Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 8314 results

  1. Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair

    Topic prioritisation

  2. Sternoclavicular joint replacement for arthritis

    Topic prioritisation

  3. Total hip arthroplasty using the superpath approach for osteoarthritis

    In development Reference number: GID-IPG10204 Expected publication date: TBC

  4. Minimally invasive surgical evacuation of intracerebral haemorrhage using endoscopic assisted clot aspiration

    Topic prioritisation

  5. Thromboaspiration for Intermediate risk Pulmonary Embolism

    Topic prioritisation

  6. Electrosurgery (diathermy and coblation) for tonsillectomy

    Topic prioritisation

  7. Extracorporeal shockwave therapy for refractory plantar fasciitis

    Topic prioritisation

  8. Automated percutaneous mechanical lumbar discectomy

    Topic prioritisation

  9. Miniature lens system implantation for advanced age-related macular degeneration

    Topic prioritisation

  10. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

  11. Oveporexton for treating type 1 narcolepsy [ID6622]

    Awaiting development Reference number: GID-TA11820 Expected publication date: TBC

  12. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

  13. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

  14. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

  15. Psoriasis: assessment and management (CG153)

    In development Reference number: GID-NG10448 Expected publication date: TBC